Shots:
- Ethris has dosed the first pts in a P-IIa trial of ETH47 for asthma symptom reduction after rhinovirus challenge, building on P-I trial data, which showed strong respiratory tract activity, local IFNλ induction, antiviral gene activation, & no systemic exposure
- The P-IIa trial will evaluate ETH47 vs PBO in ~50 adults with asthma who will undergo a rhinovirus challenge, with the 1EP assessing the impact of ETH47 on respiratory symptoms using the Lower Respiratory Symptom Score (LRSS)
- Ethris plans to advance ETH47 into a broader P-IIb study following the trial completion, with an aim to further evaluate its potential to reduce asthma exacerbations & improve patient outcomes
Ref: Businesswire | Image: Ethris | Press Release
Related News:- Ethris Reports Topline Data from P-I trial of ETH47 for Uncontrollable Asthma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
